tiprankstipranks
Advertisement
Advertisement
Balancing Safety Concerns and Long-Term Opportunity: Justifying a Buy Rating on Aardvark Amid ARD-101 Clinical Risks
PremiumRatingsBalancing Safety Concerns and Long-Term Opportunity: Justifying a Buy Rating on Aardvark Amid ARD-101 Clinical Risks
1M ago
Closing Bell Movers: Core Labs falls after below-consensus pre-announcement
Premium
The Fly
Closing Bell Movers: Core Labs falls after below-consensus pre-announcement
1M ago
Aardvark Therapeutics files $400M mixed securities shelf
Premium
The Fly
Aardvark Therapeutics files $400M mixed securities shelf
1M ago
Aardvark Therapeutics price target lowered to $45 from $50 at Cantor Fitzgerald
PremiumThe FlyAardvark Therapeutics price target lowered to $45 from $50 at Cantor Fitzgerald
2M ago
Aardvark Therapeutics price target lowered to $9 from $26 at BTIG
Premium
The Fly
Aardvark Therapeutics price target lowered to $9 from $26 at BTIG
2M ago
Aardvark Therapeutics price target lowered to $21 from $35 at Oppenheimer
Premium
The Fly
Aardvark Therapeutics price target lowered to $21 from $35 at Oppenheimer
2M ago
Aardvark Therapeutics downgraded to Hold from Buy at Stifel
PremiumThe FlyAardvark Therapeutics downgraded to Hold from Buy at Stifel
2M ago
Aardvark Pauses ARD-101 Phase 3 HERO Trial Enrollment
Premium
Company Announcements
Aardvark Pauses ARD-101 Phase 3 HERO Trial Enrollment
2M ago
Aardvark Therapeutics down 54% to $5.70 after pausing Phase 3 HERO trial
Premium
The Fly
Aardvark Therapeutics down 54% to $5.70 after pausing Phase 3 HERO trial
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100